Nav: Home

SWOG researchers go digital at ASCO20 Virtual Scientific Program

May 18, 2020

PORTLAND, OR - Researchers from SWOG, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, will make 31 presentations as part of the ASCO20 Virtual Scientific Program, the online annual meeting of the American Society of Clinical Oncology (ASCO), which runs May 29-31.

Due to the coronavirus pandemic, ASCO officials cancelled the annual Chicago meeting, the world's largest cancer research conference, and switched to an online format. About 2,215 abstracts will be presented over three days, and more than 3,400 abstracts were accepted for online publication. SWOG investigators will report on trials involving cancer treatment, prevention, and care strategies, as well as results of the first trial run through the NCI's National Clinical Trials Network (NCTN) to focus on financial toxicity - the severe financial and emotional toll exacted on patients by the costs of their cancer care.

Davendra Sohal, MD, MPH, an associate professor at the University of Cincinnati, will deliver an oral presentation on the primary findings from S1505, a randomized SWOG trial that compares two common chemotherapy regimens for early-stage pancreatic cancer, and tests chemotherapy prior to pancreatic cancer surgery.

In S1505, one group of pre-surgery patients received modified FOLFIRINOX, or mFOLFIRINOX, a combination of three chemotherapy drugs - fluorouracil, irinotecan, and oxaliplatin. The other group received a combination of gemcitabine and nab-paclitaxel. Sohal and his team found that chemotherapy treatment prior to surgery results in good outcomes - regardless of the drugs patients receive. Of the patients who received mFOLFIRINOX, 73 percent underwent surgery for their pancreatic cancer, while 70 percent of patients who received gemcitabine and nab-paclitaxel underwent surgery. Two years after treatment, 43 percent and 47 percent of all eligible patients who started treatment were alive in the mFOLFIRINOX and gemcitabine and nab-paclitaxel arms, respectively.

"We didn't find that one regimen was better than the other," Sohal said. "We did demonstrate that treating pancreatic cancer patients with chemotherapy before surgery can be done safely, and we established a benchmark with this approach, which can help us build future trials that can test other pancreatic cancer drugs and further refine pre-surgery chemotherapy treatment."

Here are other SWOG highlights of the ASCO20 Virtual Scientific Program:
  • Results from S1211 will be orally presented by Saad Usmani, MD, a hematologist with Atrium Health and co-vice chair of SWOG's myeloma committee. Usmani's phase II SWOG study is the first randomized trial comparing treatments for high-risk multiple myeloma, a difficult-to-treat version of this blood cancer for which there is no standard of care. Usmani and his team compared the effects of eight cycles of chemotherapy with lenalidomide, bortezomib, and dexamethasone induction with or without the addition of elotuzumab. Results were negative; The addition of elotuzumab didn't offer a significant benefit. However, patients on both arms of the trial appear to have better progression-free survival, and lived much longer, than high-risk multiple myeloma patients typically do. This finding casts a positive light on combination treatment for this disease, and sets a tangible benchmark for the next SWOG phase III trial.

  • Results from S1416 will be orally presented by Priyanka Sharma, MD, vice chair of SWOG's breast cancer research committee and professor of medicine at the University of Kansas Cancer Center. Eve Rodler, MD, of the University of California Davis Comprehensive Cancer Center, serves as co-leader of S1416. More than half of all cases of triple negative breast cancer (TNBC) demonstrate DNA repair deficiency, which can be due to an inherited, or germline mutation, in the BRCA gene, or due to other causes leading to tumors that appear "BRCA-like." In other words, they behave like tumors caused by a BRCA mutation but don't have an inherited gene abnormality. In germline BRCA mutation associated breast cancers, this DNA repair deficiency is successfully treated with PARP inhibitors, and Sharma and Rodler wanted to see if these drugs could also be effective for BRCA-like cancers. In S1416, patients were treated either with standard cisplatin chemotherapy and a placebo, or cisplatin plus veliparib, an investigational PARP inhibitor. Patients with germline BRCA normal but BRCA-like TNBC who got the investigational drug in addition to cisplatin had significantly improved progression-free survival and showed a trend towards improved overall survival. NCI funded the study with AbbVie Inc. providing veliparib to support the study through a Cooperative Research and Development Agreement with NCI.

  • Results from S1417CD will be presented in a poster discussion session by Veena Shankaran, MD, MS, co-director of the Hutchinson Institute for Cancer Outcomes at Fred Hutchinson Cancer Research Center. Shankaran's SWOG trial, S1417CD, is the first prospective, multicenter study of financial toxicity. The primary goal was to determine how often patients with metastatic colorectal cancer experience financial hardship over the course of their treatment. Patients filled out questionnaires assessing assets, debt, spending, stress level, and quality of life when they enrolled in the trial, then subsequently three, six, nine and 12 months into their treatment. Dr. Shankaran and her team also pulled patients' credit reports at the trial's start and finish. Results are arresting. Three out of four patients experienced major financial hardship, defined as taking on credit card debt, taking out a loan, having a 20 percent or greater drop in income, or selling or refinancing a home. What's more, most patients enrolled in the trial were not considered financially vulnerable. Shankaran said the findings underscore the need for clinical and policy solutions, such as early financial navigation for patients and the elimination of cost sharing between patients and their insurance companies.

  • Results from one cohort of S1609 will be presented in a poster session by Sylvia Adams, MD, a SWOG and ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) investigator and professor of medicine at the Perlmutter Cancer Center at New York University Langone Health. Adams wanted to test immunotherapy drugs to treat metaplastic breast cancer, a concept she came up with through ECOG-ACRIN, which is also part of the NCTN. At the suggestion of the NCI, she found a home for her idea in DART, short for Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors, a unique SWOG trial testing the immunotherapy combination of ipilimumab plus nivolumab in a variety of rare cancers. Metaplastic breast cancer is a rare form of TNBC that's actually a hybrid, including cells from the breast and tissue such as muscle or bone. These unique features make this cancer very difficult to treat, and most patients die within nine months of developing metastatic disease. In this sub-set of DART, 17 eligible patients with metaplastic breast cancer received the immunotherapy combination. Three had positive, lasting responses; their tumors shrank significantly and all three remain alive and progression-free 23 to 27 months after treatment. While one patient died on the study, and some experienced side effects such as fatigue, Adams said results are promising, leading her team to study trial tissue samples to determine if there is a biological reason behind the positive responses. S1609 was sponsored by NCI and Bristol-Myers Squibb Company provided nivolumab to support the study through a Cooperative Research and Development Agreement with NCI.

"I'm particularly impressed with this year's ASCO presentations," said SWOG Chair Charles D. Blanke, MD. "They spotlight some of our most ground-breaking clinical trials in recent years, and are a testament to the creativity, ambition, and tenacity of SWOG researchers."
-end-
SWOG Cancer Research Network is part of the National Cancer Institute's National Clinical Trials Network and the NCI Community Oncology Research Program, and is part of the oldest and largest publicly-funded cancer research network in the nation. SWOG has nearly 12,000 members in 47 states and six foreign countries who design and conduct clinical trials to improve the lives of people with cancer. SWOG trials have led to the approval of 14 cancer drugs, changed more than 100 standards of cancer care, and saved more than 3 million years of human life. Learn more at swog.org.

SWOG

Related Cancer Articles:

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.
Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.
Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.